Sign In
24 Oct 2013 17:55

For immediate release | 24 October 2013 |
Â
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Â
Share Options
Â
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 23 October 2013 it awarded the following options over ordinary shares of the Company to certain Directors.
Â
Name | Position | Number of share options awarded | Exercise price per share | Date of vesting | Percentage of issued ordinary share capital |
Anthony Booley | Executive Director | 400,000 | 35.75p | 23 October 2018 | 0.16% |
Peter Butterfield | Executive Director | 400,000 | 35.75p | 23 October 2018 | 0.16% |
Richard Wright | Finance Director | 400,000 | 35.75p | 23 October 2018 | 0.16% |
Â
Â
For further information:
Â
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive | |
Richard Wright, Finance Director | |
 | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan | |
Corporate Broking: David Poutney |
Â
Notes to editors:
Â
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Â
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Follow the stocks
